semaglutide and cancer GLP-1 drugs cancer: the headline is exciting. The full picture is more nuanced. New research from @ascocancer 2026 shows patients on GLP-1 medications like were up to 50% less likely Semaglutide decelerates the growth and

M., & Frauwirth, K

In this episode John and Professor Shah open with why insulin alone has structural limitations in type 1 diabetes, work through how GLP-1 therapies act on the body, and then walk the trial evidence from the early exenatide and liraglutide studies to the more recent semaglutide and tirzepatide data

(Wegovy, Mounjaro & the New Pill, 2026) Updated 22/06/26 Based on the available clinical evidence, Mounjaro (tirzepatide) and Wegovy (semaglutide) are both well tolerated, but most people find Mounjaro causes fewer gastrointestinal side effects at comparable doses, with lower rates of nausea and a higher likelihood of completing treatment

A meta-analysis has demonstrated that long-acting GLP-1 RAs exert greater glucose-lowering and weight-reducing effects compared to short-acting formulations [39]

Jomova K, Alomar SY, Nepovimova E, Kuca K, Valko M

For example, the team recognized that it needed an equal seat at the table with other team members, and should be viewed as data-driven, trusted advisors